The market review of drugs for the prevention and treatment of urogenital symptoms in the pre- and postmenopausal period
DOI:
https://doi.org/10.24959/sphhcj.19.163Keywords:
pharmaceutical market, medicines, menopause, urogenital symptoms, marketing researchAbstract
In 60-80 % of premenopausal or postmenopausal women various clinical manifestations of the estrogen-deficiency state may appear, i.e. climacteric disorders. The structure of the domestic market of drugs used in these cases is quite extensive and includes both hormonal and non-hormonal medicines, homeopathic, medicinal plant raw material, and others.
Aim. To review the market of drugs for the prevention and treatment of urogenital symptoms in the pre- and postmenopausal period in order to identify marketing opportunities for domestic pharmacy.
Materials and methods. The study was conducted using the structural analysis, logical and graphical methods, and marketing analysis methods.
Results. The dynamics of changes and trends in the development of the Ukrainian market for medicinal products of groups of bio-identical estrogens (preparations of G03C A03 estradiol valerite, G03C A07 estron, G03C A04 estriol, G01CA57 conjugated estrogens), G01A X14 enzymes of lactic acid bacteria, progestagens (G03D B01 Dihydroxederosone, G03D A04 Progesterone G03D A02 Medroxyprogesterone acetate, G03F A01 Norethisterone, G03A D01 Levonorgestrel), combined drugs (a combination of estrogen components with progestogen), steroids and combinations of herbal products have been determined. The structure of the market by the number of names, forms of release, manufacturer countries, and the composition has been studied. By the structure of the manufacturer countries the market of these groups of medicines is import-dependent: the share of the Ukrainian drugs in any group does not exceed 12 %. The market of non-hormonal drugs used in the treatment and prevention of urogenital malformations in the menopause has been also described. It is constantly replenished with drugs of the local action (which belong to the groups Medical products 22 and Cosmetics 06). Active substances of plant origin, as well as hyaluronic, lactic, ascorbic acids, vitamins are the most common in their composition. The market is also import-dependent; drugs belong to the high cost category.
Conclusions. Based on the changes identified definite proposals have been developed for the domestic pharmaceutical industry − the market has a very small range of domestic medicinal products that can be used for the treatment and prevention of urogenital disorders in the menopause. For producers they are interesting due to the possibility of using the domestic raw material base, as well as the fact that this group of drugs is included in the high cost niche. Based on the lower cost a domestic manufacturer will be able to offer the market a competitive price, make drugs more affordable, without losing the necessary profitability.References
Rogovskaia, S. I., Semenova, E. N. (2016). Slovo pro zdorov’ia, 4. Available at: https://ozdorovie.com.ua/novyie-podhodyi-k-probleme-suhosti-vlagalishha-u-zhenshhin/
Zalizniak, V.O. (2016). Suchasni pohliady na zamisnu hormonalnu terapiiu v pery- ta postmenopauzi. Zaporizhzhia: ZDMU, 82.
Yermakova, E. I., Balan, V. E., Tikhomirova, E. V., Lazareva, I. N., Lapina, A. V., Panina, E. M. (2017). Rossiiskii vestnik akushera-ginekologa, 6, 89-95. doi: 10.17116/rosakush201717689-95.
Mnushko, Z. N., Pestun, I. V. (2008). Teoriia i praktika marketingovykh issledovanii v farmatsii.Kharkov: Izdatelstvo NFaU, 308.
Balan, V. E., Kovaleva, L. A., Tikhomirova, E. V. (2016). Meditsinskii sovet, 12, 98-101. doi: 10.21518/2079-701X-2016-12-98-101.
Zaichenko, H. V., Horchakova, N. O., Stryha, O. A., Yakovleva, N. Yu., Ruban, O. I. (2017). Visnyk problem biolohii i medytsyny, 1 (135), 33-42.
Stroitelev, V. (1997). Vestn. novykh med. tekhnol., 3, 98–104.
Baza danykh “Morion”. Available at: https://pharmbase.com.ua/ru/optovye-predlozheniya/ − dated 20.09.2016.
Derzhavnyi reiestr likarskykh zasobiv Ukrainy. Available at: http://www.drlz.com.ua/.
Kompendium: lekarstvennye preparaty. Available at: http://compendium.com.ua/.
Brif-analiz farmrynka: itogi noiabria 2016. (2016). Ezhenedelnik “Apteka”, 1067 (46). Available at: http://www.apteka.ua/article/397246].
Al-Baghdadi, O. (2009). Topical estrogen therapy in the management postmenopausal vaginal atrophy: an up-to-date overview. Climacteric, 12 (2), 91–105. doi: 10.1080/13697130802585576.
Sinha, A., Ewies, A. A. (2013). Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview. Climacteric, 16, 305-312. doi: 10.3109/13697137.2012.756466.
Griebling, T. L., Liao Z., Smith P. G. (2012). Systemic and topical hormone therapies reduce vaginal innervation density in postmenopausal women. Menopause, 19, 630-635. doi: 10.1097/gme.0b013e31823b8983.
Frank, S. M., Ziegler, C., Kokot-Kierepa, M., Maamari, R., Nappi, R. E. (2013). Vaginal Health: Insights, Views & Attitudes (VIVA) survey — Canadian cohort. Menopause Int., 19 (1), 20-27. doi: 10.1258/mi.2012.012034
Pastore, L. M., Carter R. A., Hulka B. S., Wells, E. (2004). Self-reported urogenital symptoms in postmenopausal women: Women’s Health Initiative. Maturitas, 49, 292-303. doi: 10.1016/j.maturitas.2004.06.019.
Stuenkel, C. A., Davis, S. R., Gompel, M. A., Pinkerton, J. V., Santen, R. J. (2015). Menedzhment klimakteriiu, 6 (26). http://press.endocrine.org/суткиoi/abs/10.1210/jc.2015-2236?journalCode=jcem
Baber, R. J., Panay, N., Fenton, A. (2016). 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric, 19.2, 109–150. doi: 10.3109/13697137.2015.1129166.
Santoro, N., Epperson, C. N., Mathews, S. B. (2015). Menopausal symptoms and their management. Endocrinol Metab Clin N Am., 44 (3), 497–515. doi: 10.1016/j.ecl.2015.05.001.
Thompson, J., Ritenbaugh, C., Nichter, M. (2017). Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making. BMC Womens Health, 17, 97. doi: 10.1186/s12905-017-0449-0.
Downloads
Published
Issue
Section
License
Copyright (c) 2019 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
